Cargando…
A phase 1 double‐blind, placebo‐controlled study of zuranolone (SAGE‐217) in a phase advance model of insomnia in healthy adults
OBJECTIVE: To evaluate single zuranolone (SAGE‐217) 30 or 45 mg doses in a 5‐h phase advance insomnia model. METHODS: In this double‐blind, three‐way crossover study, healthy adults received placebo (n = 41), zuranolone 30 mg (n = 44), and zuranolone 45 mg (n = 42) across three treatment periods. Sl...
Autores principales: | Bullock, Amy, Gunduz‐Bruce, Handan, Zammit, Gary K., Qin, Min, Li, Haihong, Sankoh, Abdul J., Silber, Christopher, Kanes, Stephen J., Jonas, Jeffrey, Doherty, James |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286466/ https://www.ncbi.nlm.nih.gov/pubmed/34352138 http://dx.doi.org/10.1002/hup.2806 |
Ejemplares similares
-
Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial
por: Deligiannidis, Kristina M., et al.
Publicado: (2021) -
SAGE-217, A Novel GABA(A) Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies
por: Hoffmann, Ethan, et al.
Publicado: (2019) -
Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA(A) receptor positive allosteric modulator
por: Althaus, Alison L., et al.
Publicado: (2020) -
Rapid improvements in MADRS with zuranolone in major depressive disorder and postpartum depression: results from the LANDSCAPE/NEST clinical development programmes
por: Clayton, A. H., et al.
Publicado: (2023) -
Clinical Efficacy of a 2-Week Treatment Course of Zuranolone for the Treatment of Major Depressive Disorder and Postpartum Depression: Outcomes From the Clinical Development Program
por: Clayton, A., et al.
Publicado: (2022)